Mesenchymal Stem Cells: Repair Crews, Immune Referees, and the Clinical Reality

The phrase "stem cell therapy" can sound almost magical: collect versatile cells, place them into an injured body, and watch them rebuild whatever is broken. Mesenchymal stem cells, or MSCs, have attracted exactly this kind of attention. Researchers have studied them in bone and joint disease, immune disorders, heart failure, neurological conditions, lung injury, diabetes, and many other illnesses. A major 2025 review describes an enormous research landscape, including laboratory work and clinical trials across multiple organ systems [1].

The science is genuinely exciting, but the simple repair-cell story is incomplete. MSC preparations differ depending on where the cells came from, how they were grown, how many times they divided in a laboratory, how they were stored, and how they were delivered. Their effects may come less from permanently replacing damaged tissue and more from briefly changing the local biological conversation. That distinction helps explain why impressive laboratory results have not consistently become durable benefits in people.

What are mesenchymal stem cells?

MSCs are adult, non-blood-forming cells that can be isolated from tissues such as bone marrow, fat, umbilical cord, placenta, and dental pulp. Under laboratory conditions, they can attach to plastic, multiply, and develop features of bone, cartilage, and fat cells. They are multipotent, meaning they can form several related cell types, but they are not equivalent to embryonic stem cells and cannot naturally create every tissue in the body.

Even their name needs a footnote. The International Society for Cell & Gene Therapy recommends using "mesenchymal stromal cells" unless true stem-cell properties have been rigorously demonstrated. It also recommends identifying the tissue source and testing functions relevant to the intended treatment [2]. In everyday writing, MSC still often means mesenchymal stem cell. Scientifically, however, "stromal cell" is usually the more cautious label.

A mobile pharmacy, not merely a bag of spare parts

The early hope was that infused MSCs would travel to an injury, settle there, and turn into replacement tissue. That can occur under some experimental conditions, but it does not appear to explain most observed effects. Many administered cells survive only briefly or become trapped in organs such as the lungs. Yet they may still influence healing because they release a mixture of growth factors, cytokines, chemokines, lipids, and genetic signals. This collection of secreted material is sometimes called the secretome.

One useful metaphor is a temporary mobile pharmacy. Rather than becoming the new building, the cells deliver instructions to the construction crew already on site. They can influence macrophages, T cells, B cells, dendritic cells, blood-vessel formation, cell survival, and scar formation. Small membrane packages called extracellular vesicles can carry proteins, fats, and RNA from MSCs to other cells. Reviews conclude that this paracrine signaling—communication with nearby or distant cells—is a major part of MSC immune regulation [3].

This behavior is not automatically anti-inflammatory in every setting. MSCs respond to their environment. Signals in injured or infected tissue can change what they release, and an immune response that should be restrained in one disease may be necessary in another. The same flexibility that makes MSCs interesting also makes them difficult to standardize as a drug.

Why two MSC products may not be the same treatment

A bone-marrow-derived product from an older donor is not necessarily interchangeable with an umbilical-cord-derived product. Fresh cells may behave differently from frozen and thawed cells. Oxygen level, nutrients, culture medium, expansion time, dose, route, and donor health can all influence potency. A local injection into a knee is also biologically different from an intravenous infusion for lung or immune disease.

Researchers therefore need more than a label saying "contains MSCs." They need identity tests, sterility testing, viability measurements, manufacturing consistency, and a potency assay showing that the product can perform the relevant biological function. Without those controls, trials that appear to test the same idea may actually be testing quite different living products.

What have clinical studies found?

The answer depends on the disease, product, delivery method, and outcome. Knee osteoarthritis is one of the most heavily marketed uses. A 2024 systematic review included 16 randomized trials with 807 participants. At three to six months, MSC therapy probably produced little to no clinically important improvement in pain or physical function compared with placebo or usual care, despite a small numerical difference in pain [4]. This is a useful reminder that a statistically detectable change may still be too small for patients to notice.

Heart failure research offers a different kind of mixed signal. A 2024 meta-analysis of 36 randomized trials found a modest improvement in left ventricular ejection fraction, a measurement of how much blood the heart pumps with each beat. However, MSC treatment did not significantly reduce major adverse cardiovascular events [5]. A better imaging measurement is encouraging, but it is not the same as helping people live longer, avoid hospitalization, or feel better.

Results can also change when an approach is tested more broadly. Darvadstrocel, an adipose-derived MSC product, initially showed promise for difficult perianal fistulas in Crohn disease. In the larger ADMIRE-CD II phase 3 trial reported in 2026, 568 patients received darvadstrocel or placebo after the same surgical preparation. Combined remission at 24 weeks occurred in 48.8% of the treatment group and 46.3% of the placebo group, a nonsignificant difference [6]. The negative confirmatory trial does not erase earlier findings; it shows why replication matters.

What do we know about safety?

Controlled trials have generally produced a reassuring short-term safety signal, but "safe enough to study" is not the same as "proven safe for routine use." A 2026 meta-analysis examined 42 randomized trials involving 2,280 adults who received intravascular umbilical-cord-derived MSCs or a control treatment. Fever was more common with MSCs. The analysis did not detect higher rates of infection, death, malignancy, abnormal tissue formation, or blood clots, and no included trial stopped early for safety [7].

Those findings are encouraging but limited by varied diseases, products, doses, and follow-up periods. Rare or delayed harms can be missed when trials are small. Risks also include contamination, immune reactions, clotting, inappropriate tissue effects, and complications from the procedure used to deliver the cells. A product prepared in a regulated clinical trial cannot be assumed equivalent to an injection sold by a commercial clinic.

The marketing has moved faster than the medicine

The United States now has one important, tightly defined example of successful translation. In December 2024, the Food and Drug Administration approved Ryoncil, a donor-derived bone-marrow MSC therapy, for steroid-refractory acute graft-versus-host disease in children two months of age and older. It was the first FDA-approved MSC therapy [8]. This approval supports the platform's medical potential, but only for that specific product, population, dose, and indication. It does not validate generic "stem cell injections" for unrelated conditions.

The FDA continues to warn consumers about unapproved human cell and tissue products marketed for broad lists of diseases. Reported concerns include contamination, immune reactions, unintended tissue growth, tumors, and delaying effective care [9]. Patients should be especially cautious when one clinic claims that essentially the same vial can treat arthritis, dementia, heart disease, fatigue, autism, and aging. A legitimate clinical study identifies the exact product, disease, dose, eligibility criteria, oversight, and measured outcome. Paying to receive an experimental product is not proof that the treatment is part of a properly authorized trial.

Do MSCs have a role in longevity?

Aging involves chronic low-grade inflammation, impaired tissue repair, immune dysfunction, fibrosis, and changes in the signals exchanged among cells. Because MSCs can influence several of these processes, they are relevant to longevity research. That connection is mechanistically plausible, but it remains indirect. No good clinical evidence shows that MSC infusions slow whole-body human aging, extend lifespan, or provide general rejuvenation.

The most realistic future may be narrower and more useful: carefully defined MSC or cell-derived products for particular conditions, given at a specific disease stage and manufactured to a reproducible standard. Researchers are also studying extracellular vesicles and engineered MSCs, hoping to capture useful signals while improving targeting and consistency. These approaches remain experimental and bring their own manufacturing and safety questions.

The bottom line

Mesenchymal stem or stromal cells are neither miracle cures nor failed science. They are adaptable living systems that can alter inflammation, cellular communication, and repair. The underlying biology is strong, and some clinical signals deserve continued investigation. Yet results are inconsistent, products are heterogeneous, and improvements in laboratory markers do not automatically translate into better health or longer life.

For now, the evidence supports optimism with guardrails. MSC therapy should be judged product by product, disease by disease, and outcome by outcome. The path forward requires larger randomized trials, transparent reporting, standardized manufacturing, long-term follow-up, and endpoints that matter to patients. That may sound less dramatic than a universal repair cell, but it is how a promising biological idea becomes reliable medicine.

References

[1] Han X, Liao R, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Ther. 2025;10(1):262. doi:10.1038/s41392-025-02313-9.

[2] Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019-1024. doi:10.1016/j.jcyt.2019.08.002.

[3] Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med. 2019;8(7):1025. doi:10.3390/jcm8071025.

[4] Sadeghirad B, Rehman Y, Khosravirad A, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: a systematic review and meta-analysis of randomized trials. Osteoarthritis Cartilage. 2024;32(10):1207-1219. doi:10.1016/j.joca.2024.04.021.

[5] Hosseinpour A, Kamalpour J, Dehdari Ebrahimi N, et al. Comparative effectiveness of mesenchymal stem cell versus bone-marrow mononuclear cell transplantation in heart failure: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2024;15(1):202. doi:10.1186/s13287-024-03829-7.

[6] Colombel JF, Garcia Olmo D, Chen ST, et al. Darvadstrocel in patients with Crohn's disease with complex perianal fistulas: the ADMIRE CD II phase 3 randomized trial. Gastroenterology. 2026; online ahead of print. doi:10.1053/j.gastro.2025.12.033.

[7] Hum C, Poliwoda J, Lalu M, et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Transl Med. 2026;15(6):szag029. doi:10.1093/stcltm/szag029.

[8] U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-Versus-Host Disease. December 18, 2024.

[9] U.S. Food and Drug Administration. Patient and Consumer Warning About Potential Serious Risks of Harm Following Use of Unapproved Products From Human Cells or Tissues. Accessed August 9, 2026.